Company intelligence / Profile preview

Aegle Therapeutics

Miami, Florida, United Statesaegletherapeutics.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Aegle Therapeutics is currently conducting Phase 1/2a clinical trials for AGLE-102 in patients with Dystrophic Epidermolysis Bullosa (DEB) and severe burns. The first patient in the DEB trial was dosed in August 2024. The company has reported compelling clinical results in burns.

Therapeutic areas: ImmunologyRare DiseasesDermatology
Modalities: Extracellular vesicle (EV) therapyMesenchymal stem cell-derived extracellular vesicles
Industry: Biotech

Drug pipeline

1 asset

AGLE-102

Beyond the preview

Go deeper on Aegle Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aegle Therapeutics.

Explore the full profile